A report into the Narcotic Drugs Act (ND Act) has recommended several changes to medical cannabis regulation in Australia.
The report, compiled by Australian National University Professor John McMillan and commissioned by Health Minister Greg Hunt, put forth 26 recommendations aimed at improving the regulatory framework for cultivating, producing and manufacturing medicinal cannabis.
One of the key recommendations is to simplify the current licensing regime of multiple separate cannabis production licences, to a single licence scheme, which would reduce the regulatory burden on both the administration and businesses within in the industry.
The report also questioned if cannabidiol (CBD) should be classed as a drug. According to the World Health Organization, in humans, CBD – the non-psychoactive cannabinoid found in the cannabis plant, “exhibits no effects indicative of any abuse or dependence potential”.
Read the full report here.
In conjunction with the HMRI and lead biomedical scientist Dr Matt Dun, we’re investigating the anticancer properties of our plant varieties. Dr Matt Dun shares his initial thoughts on the joint research project.
We’re thrilled to announce we have received our export licence from the Drug Control Section of the ODC (Office of Drug Control). We’re firmly on course to continue to lead the way and be the first medicinal cannabis company in Australia to export cannabis flower to the EU since export was legalised in 2018.
We are focused on research and development, partnering with leading scientists and medical institutions to develop cannabinoid medicines that offer safe and effective therapeutic benefits.LEARN ABOUT ANTG HERE >